Biotest AG: research into additional indications for monoclonal antibody BT-061
Biotest AG / Research Update
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Biotest: research into additional indications for monoclonal antibody
BT-061
- Research cooperation agreed with the University of Mainz for BT-061
- Biotest’s industrial property rights extended
- Rheumatoid arthritis and psoriasis trials are progressing as planned
Dreieich, 5 May 2008. The Biotest Group and Johannes Gutenberg University
in Mainz have concluded an agreement which grants Biotest access to
additional results from preclinical trials investigating the effect of
monoclonal antibodies on regulatory T cells. A research cooperation, which
forms part of the agreement is initially scheduled to run for two years.
The main objective is to carry out preclinical investigations with the
BT-061 monoclonal antibody in further indications using animal models. Both
parties have agreed not to comment on the details of the cooperation.
The university’s dermatology clinic has many years of expertise in the
field of immunoregulation through regulatory T cells. Under the cooperation
agreement, the preclinical evaluation of the BT-061 monoclonal antibody
will be carried out in allergic indications; corresponding test systems
were established as part of an earlier research cooperation.
The first international patent for BT-061 has since been granted in certain
countries and is currently being examined by further patent offices
worldwide. Biotest has also submitted other patent applications for
therapeutic use. The patent portfolio was also recently extended with
further international applications for BT-062, which is currently under
development.
Meanwhile, the clinical development of BT-061 in the key indications of
rheumatoid arthritis and psoriasis is progressing according to plan. First
efficacy results are expected towards the middle of this year. Once it has
obtained these data from the currently ongoing clinical trials, Biotest
will commence negotiations with potential international development and
marketing partners of the pharmaceutical industry.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and asset
situation of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest AG, Dreieich, Germany, is a company that researches and
manufactures pharmaceutical, biotherapeutic and diagnostic products and has
specialised in immunology and haematology. In its Pharmaceutical segment,
Biotest develops immunoglobulins, clotting factors and albumins based on
human blood plasma. These are used for diseases of the immune system or
haematopoietic system. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and blood cancer. The Diagnostic
segment spans reagents and immunological diagnostics which are used, for
example, in blood transfusions and transplants. Biotest has around 1,800
employees worldwide and its shares are listed in the Frankfurt Stock
Exchange's Prime Standard and S-DAX.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Michael Ramroth
Tel: +49 (0) 6103 801-338
Fax: +49 (0) 6103 801-347
e-mail: michael_ramroth@biotest.de
WKN, ISIN ordinary share: 522720, DE0005227201
WKN, ISIN preference share: 522723, DE0005227235
Listed: Prime Standard/official trading
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
05.05.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-8 80
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227201, DE0005227235
WKN: 522720, 522723
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
